articleNature MedicineSep 1, 2007Closed access

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

STSandeep T. PatilLZLu ZhangFMFerenc MartényiSLStephen L. LoweKJKimberley Jackson

Eli Lilly (United States) · Merck & Co., Inc., Rahway, NJ, USA (United States) · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,034
total citations
FWCI
41.76
Percentile
100%
References
30
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Olanzapine
  • Antipsychotic
  • Metabotropic receptor
  • Psychology
  • Schizophrenia (object-oriented programming)
  • Placebo
  • Internal medicine
  • Medicine
No related works found for this paper.